Skip to main content
OpenTrials
Completed

NCT Number: NCT00531661

CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients

This is a prospective, multi-center, randomized, single-blind clinical trial conducted in the United States (US). The objective of the study is to evaluate the safety and efficacy of the HF Pressure Measurement System in reducing heart failure (HF) related hospitalizations in a subset of subjects suffering from HF.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Heart Failure, Congestive Cardiovascular Diseases Heart Diseases Heart Failure

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CardioMEMS Investigational Sites

Nationwide, Georgia, 30313, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of HF ≥ 3 months, with either preserved or reduced LVEF
  • Diagnosis of NYHA Class III HF (historical assessment documented at screening visit)
  • Subjects with reduced LVEF must be receiving a beta blocker for 3 months and an ACE-I or ARB for one month unless in the investigator's opinion, the subject is intolerant to beta blockers, ACE-I or ARB. Beta blockers and ACE-I (or ARB) doses should be stable for one month prior to study entry.
  • At least 1 HF hospitalization within 12 months of Screening Visit
  • Subjects with pulmonary artery branch diameter sized between 7mm and 15mm (implanted vessel)

Exclusion criteria

  • Subjects with history of recurrent (> 1) pulmonary embolism or deep vein thrombosis
  • Subjects, in the Investigator's opinion, unable to tolerate a right heart catheterization
  • Subjects who have had a major cardiovascular event (e.g., myocardial infarction, stroke) within 2 months of Screening Visit
  • Subjects with Cardiac Resynchronization Device (CRT) implanted ≤ 3 months prior to enrollment
  • Subjects with a Glomerular Filtration Rate (GFR) <25 ml/min who are non-responsive to diuretic therapy or who are on chronic renal dialysis
  • Subjects likely to undergo heart transplantation within 6 months of Screening Visit
  • Subjects with congenital heart disease or mechanical right heart valve(s)
  • Subjects with known coagulation disorders
  • Subjects with a hypersensitivity or allergy to aspirin, and/or clopidogrel

Treatment and study plan

HF Pressure Measurement System

Device

A pressure sensor is intended to be implanted into the pulmonary artery at the time of Swan-Ganz catheterization.

Primary outcomes

  1. Rate of Heart Failure Related (HFR) Hospitalizations

    Time frame: 6 months

  2. Freedom From a Device/System-related Complication (DSRC).

    Time frame: 6 months

    A DSRC is an adverse event that is, or is possibly, related to the HF Pressure Measurement System and at least one the following:

    • is treated with invasive means (other than intramuscular medication or a right heart catheterization with a Swan-Ganz measurement which is used for diagnostic purposes)
    • results in the death of the subject
    • results in the explant of the device

  3. Freedom From Pressure Sensor Failure

    Time frame: 6 months

    A pressure sensor failure occurs when the sensor malfunctions to the point that no readings can be obtained from it after all attempts are exhausted including troubleshooting the system to rule out any problems with the electronic components.

Secondary outcomes

  1. Change From Baseline in Pulmonary Artery Mean Pressure

    Time frame: 6 months

    Change from baseline in pulmonary artery mean pressure was calculated using an area under the curve (AUC) methodology. All patients were instructed to take daily home readings for 180 days. By patient, a baseline average for the first 7 days of home readings was calculated. The difference between baseline and each daily reading was then determined and a corresponding daily AUC value was calculated. Finally, all daily AUC values were summed over the entire 180 day period resulting in a total AUC per patient. These data were aggregated for each randomization group and then compared. The unit of measure is mmHg x Days.

  2. Proportion of Patients Hospitalized for Heart Failure

    Time frame: 6 months

  3. Days Alive Outside of the Hospital

    Time frame: 6 months

  4. Quality of Life - Minnesota Living With Heart Failure Questionnaire (MLHFQ)

    Time frame: 6 months

    THe MLHFQ is patient self-assessment of how heart failure affects his or her daily life. To measure the effects of symptoms, functional limitations, psychological distress on an individual's quality of life, the MLHFQ questionnaire asks each person to indicate using a 6-point, zero to five, Likert scale how much each of 21 facets prevented them from living as they desired. Total scores are provided as sums. The total score scale range is 0 - 105. A lower total score is indicative of better quality of life.

Other outcomes

  1. Rate of HFR Hospitalizations

    Time frame: Study duration: average patient follow-up of 15 months

  2. Freedom From a Device/System-related Complication (DSRC)

    Time frame: Study duration: average patient follow-up of 15 months

  3. Freedom From Pressure Sensor Failure

    Time frame: Study duration: average patient follow-up of 15 months

Sponsors and collaborators

Lead sponsor

CardioMEMS

Industry

Registry information

Acronym: CHAMPION

Important dates

Study start
2007
Primary completion
2010
Study completion
2014
First posted
Sep 19, 2007
Registry last updated
Jan 28, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.